Brief: Royalty Pharma Q2 Net Income USD 351 Million
08/08/2023 12:00
Aug 08 (Reuters) - Royalty Pharma Q2 adjusted EBITDA USD 498 million. * Q2 operating income USD 249 million * Q2 operating expenses USD 289 million * Q2 pretax profit USD 351 million
Recent news on Royalty Pharma
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Royalty Pharma falls after Novartis' cholesterol drug fails in study
Brief: Royalty Pharma Announces Update On Novartis’ Phase 3 Topline Results For Pelacarsen
Teva's immune disorder drug meets main goal in mid-stage trial (updated)